The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call reflects a ...

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...